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 Abstract 
 
A brown powder and different product packages of “spice-like” herbal incenses were 
analyzed using a systematic identification approach based on liquid chromatography with 
diode array detector (HPLC-PDA) and gas chromatography mass spectrometry (GC-MS) 
with computer based library search against spectral libraries. However, the most predominant 
compound in the methanolic sample solutions could not be identified. In order to elucidate 
the chemical structure, a more extensive analysis of the material was initiated using liquid 
chromatography mass spectrometry (LC-MS), electrospray high resolution mass 
spectrometry (ESI-HRMS) and 1H, 13C and 19F nuclear magnetic resonance spectroscopy 
(NMR), which allowed the identification and characterization of the major compound as 
methyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (5F-MDMB-
PICA).  
The goal of this study is to provide analytical information for the identification of this new 




The last decade has seen the global appearance of novel drugs with (psychoactive) 
characteristics comparable to the commonly known illicit drugs of abuse; hence the term new 
psychoactive substances (NPS) was coined. Contrary to other synthetic abused drugs, most of 
these NPS have never appeared in academic research, and have never been studied. As a 
result, very little - if any- information is available regarding mode of action, human/animal 
pharmacology, or acute and chronic toxicity. Also typical is that these NPS are being actively 
sold in internet web shops, and that chemical synthesis is mostly performed under dubious 
circumstances in ill-equipped Chinese labs. In the EU alone, the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) reported in its European Drug Report 2016 the 
monitoring of more than 560 novel substances, of which 380 (70%) were detected in the last 
5 years (1). These substances can be classified according to chemical class and/or mode of 
action.  
 
The largest class of compounds currently monitored by the European Early Warning System 
consists of synthetic cannabinoids. This class consists almost exclusively of cannabinoid 
agonists, with high affinities for cannabinoid receptors; both CB1 and CB2 agonists have 
been reported. The use of these substances has been recorded in several “user groups”, such 
as psychonauts, prisoners and high school students. Easy availability, the legal status, and 
sometimes low cost have been reported as motives for use of synthetic cannabinoids. Also 
people who want to avoid detection of illicit drugs (such as people undergoing regular urine 
drug screening in a judicial context) also report the use of synthetic cannabinoids. In Belgium 
however, the use of synthetic cannabinoids is generally low, although many compounds are 
detected and identified every year. The majority is seized by customs while in transit from 
foreign countries (especially China), and have other EU countries as destination. Data are 
lacking, but it is estimated that actual use of the compounds in Belgium remains limited, 
contrary to other EU member states. (2) 
 
These cannabinoids (and NPS in general) are frequently advertised as ‘legal highs’, and 
marketed as safe and legal alternatives to cannabis. However, an increasing number of papers 
is being published describing adverse effects, toxicity, and even deaths caused by the 
consumption of synthetic cannabinoids. Although these substances are sold as legal 
alternatives to (illegal) cannabis, ironically these synthetic cannabinoids can cause severe 
toxicity that has never been observed after cannabis use. For example, in July 2015 a serious 
outbreak of intoxications and fatalities after the consumption of a synthetic cannabinoid 
herbal mixture (called “Mocarz”, meaning “Strongman”) occurred in Poland. More than 200 
users were hospitalized with intoxication symptoms, and several deaths have been reported 
(3–6). Several different synthetic cannabinoids were identified in “Mocarz” herbal mixtures, 
and more specifically MDMB-CHMICA seems to have caused a lot of victims (6–9). 
Similar events on a smaller scale have also been reported throughout Europe (10), triggering 
the EMCDDA to perform a formal risk assessments for some compounds, such as MDMB-
CHMICA, with subsequent initiatives to schedule the substance at the EU level (11-13). 
 
The analytical detection of NPS remains a challenge for forensic laboratories, moreover, for 
clinical laboratories or emergency services, identification by means of second level analysis 
requires reference standard materials, methodologies and analytical equipment that are 
usually not available to every laboratory yet. Hence, this paper aims to provide a thorough 
overview of the analytical methods that were used to unequivocally identify the seized 
substance as 5F-MDMB-PICA (Figure 1). The different used methods (GC-MS, HPLC-PDA, 
ESI-LC-MS, ESI-HRMS and 1H, 13C and 19F NMR spectroscopy) will be discussed in detail. 
The results presented here are, to our knowledge, the first report of the analysis and 
identification of the synthetic cannabinoid 5F-MDMB-PICA from a seized powder and 
herbal incenses. The results may be used for analytical purposes in the clinical and forensic 
sciences in order to improve the detection of this substance both on the EU as on the 
international level. 
 
2. Materials and methods  
 
2.1 Samples and case histories 
In November 2016, a powder in an unlabeled zip-locked plastic bag and 27 product packages 
of Bonzai herbal incenses of different flavors (aluminum foils bags with content: 3 g each), 
were submitted to the laboratory for toxicological analysis. The powder was brown and 
appeared as a partially grainy, amorphous solid with a strong and unpleasant odor. It was 
stated that the powder was used as raw material in the production of the herbal incenses.  
 
2.2 Materials 
The solvents used for GC-MS and HPLC-PDA were of analytical grade. Methanol and 
acetonitrile were obtained from Fisher Chemical (Fisher Bioblock, Belgium). Water was 
purified by a Milli-Q system obtained from Merck Millipore (Darmstadt, Germany). 
Triethylammonium (TEA) phosphate buffer 1M was purchased from Sigma (Zwijndrecht, 
Belgium) and was diluted 1/40 immediately before use. Diphenylamine used as external 
standard was obtained from VWR International (Leuven, Belgium). Solvents for ESI-HRMS 
were of ULC-grade and were purchased from Biosolve (Valkenswaard, the Netherlands). 
Acetonitrile for ESI-LCMS was purchased from Merck (Darmstadt, Germany) and was of 
HPLC grade. Water was obtained from a Millipore Synergy UV apparatus (Billerica MA, 
USA). Formic acid was purchased from Sigma-Aldrich and was of mass spectrometry grade. 
Deuterated dimethyl sulfoxide (0.03%, v/v tetramethylsilane) for NMR was obtained as 
ampoules (750 µL) from Euriso-Top (Saint Aubain, France).  
 
2.3 Instrumentation and sample preparation 
 
2.3.1 Gas chromatography-mass spectrometry (GC-MS) 
For the determination of the mass spectrum of the compound, analysis of a freshly prepared 
methanolic sample solution (containing 200 µg/ml diphenylamine as external standard) was 
performed using an Agilent 6890 N gas chromatograph in combination with a Agilent 7683 
injector and an Agilent 5973 inert mass selective detector (Agilent Technologies, California, 
USA). A Varian CP-SIL 8 CB low bleed capillary column (30 m x 0.25 mm, 0.25 µm film 
thickness) was used connected to a fused silica retention gap (2.5 m x 0.25 mm). Carrier gas 
was helium at a constant flow of 1.1 ml/min. The temperature program used was as follows: 
start at 70 °C with 2 min holding time, increase to 310 °C at 8 °C/min, 9 min holding time at 
310 °C, total runtime 41 min. The temperatures of the injection port and the detector were set 
at 300 and 230 °C, respectively. The transfer line temperature was set at 280 °C. The 
injection volume was 1 µL using the splitless injection mode. Mass spectra were recorded in 
the range m/z 40-550.  
 
2.3.2  Liquid chromatography with photo-diode array detection (HPLC-PDA) 
The UV-spectrum of the compound was obtained by HPLC-PDA. A sample solution of the 
powder was prepared in methanol (1.198 mg/ml). A 50 µl aliquot was evaporated at 40 °C 
under a gentle stream of nitrogen and reconstituted in 1.0 ml initial mobile phase (containing 
20 µg/ml diphenylamine as external standard). A final concentration of 59.9 µg powder/ml 
was injected.  
A 50 µl aliquot of a crude methanol extract of the herbal incense (homogenized, 246.8 mg/ 
20 ml, sonicated for 30 min and centrifuged) was evaporated at 40 °C under a gentle stream 
of nitrogen and reconstituted in 1.0 ml of initial mobile phase (containing 20 µg/ml 
diphenylamine). A concentration of 617 µg/ml was injected.  
The HPLC-PDA analysis was performed using a Varian Prostar solvent delivery module in 
combination with a Varian Prostar 410 autosampler and Varian Prostar photodiode array 
detector. Data acquisition and analysis were performed with the Varian Star and Polyview 
software. A LiChrospher® 100 RP-18 (5 µm) (Merck, Darmstadt, Germany) was used as 
saturation column. The separation of compounds was performed in gradient mode with the 
use of a Microsorb C18 column (150 mm x 4.6 mm, 5 µm particle size, Agilent, California, 
USA) connected to a C18 guard column (4 mm x 3.0 mm, 3.5 µm particle size). The oven 
temperature was set at 35 °C. The mobile phases consisted of 25 mM TEA-phosphate buffer 
(A) and acetonitrile (B). The following gradient elution was programmed: 95 % A at time 0 
min, changed to 30 % A in 30 min and held for 5 min. The scan range was 220-340 nm and 
the chromatogram was monitored at 220 nm and 254 nm for 35 minutes. The injection 
volume was 50 µl. 
 
2.3.3  Electrospray liquid chromatography mass spectrometry (ES-LC-MS) 
A solution of the powder was prepared by dissolving the material in acetonitrile to a 
concentration of 1.0 mg/ml. A Waters® AutoPurification™ system was equipped with a 
Waters® CORTECS® column (C18, 4.6 x 100 mm, 2.7 µm particle size) and using Waters® 
MassLynx software. Optical detection was achieved using a Waters® 2998 PDA. MS-
detection was done in positive mode using a Waters® Acquity QDA detector. The mobile 
phases consisted of water/formic acid (1000:1, v/v) (A) and acetonitrile (B). Elution was 
carried out at 1.44 ml/min at 20 °C. The following gradient elution was programmed: 95% A 
at time 0, changed to 5% A over 10 min and held for 2 min. The injection volume was 5 µL. 
 
2.3.4 Electrospray high resolution mass spectrometry and molecular formula analysis (ES-
HRMS) 
 A solution of the powder was prepared by dissolving the material in acetonitrile to a 
concentration of 1.0 mg/ml. This solution was diluted 1000x with acetonitrile to a final 
concentration of 1.0 µg/ml. High resolution mass spectra were recorded on a Waters® LCT 
Premier XE (TOF) set for electrospray ionization and using Waters® Masslynx software. The 
mass was referenced using Leucine Enkephalin (Sigma-Aldrich) as an external standard. 
Spectra were generated in positive ionization mode by direct infusion of the above mentioned 
solution (10 µL) using an additional flow (150 ul/min) of acetonitrile/water/formic acid 
(1000/1000/1, v/v/v). After obtaining the high resolution mass value, a statistic ranking of the 
most probable molecular formulas was generated from a Single-Mass-Analysis using the 
Elemental-Composition function in MassLynx. 
 
2.3.5 1H, 13C and 19F nuclear magnetic resonance spectroscopy (NMR) 
To achieve secure proof of the molecular structure the 1H, 13C and 19F nuclear magnetic 
resonance (NMR) spectrum of the compound was assigned. A solution of the powder in 
DMSO-d6 (20 mg in 750µL) was prepared in a Wilmad® NMR tube (5 mm diameter) and 
sealed using a polypropylene cap. This sample was used for all three types (1H, 13C and 19F) 
of NMR. All NMR spectra were recorded at 25 °C on a 300 MHz Varian Mercury NMR 
spectrometer and processed using the Varian VNMRJ 3.2 software package. Referencing of 
NMR spectra was carried out according to Gottlieb et al. (14) or IUPAC referencing with 
CFCl3 set to 0 ppm. 
 
2.3.5.1 1H NMR spectroscopy. 
The spectrum was recorded at 300 MHz using 32 scans and was referenced to the signal of 
tetramethylsilane at 0 ppm.  
 
2.3.5.2 13C APT NMR spectroscopy. 
The spectrum was recorded at 75.4 MHz in Attached-Proton-Test mode using 22500 scans 
and was referenced to the central peak of the DMSO-d6 multiplet at 39.52 ppm. 
 
2.2.5.3 19F NMR spectroscopy. 
The spectrum was recorded at 282 MHz using 64 scans and was DMSO-d6 lock resonance 
frequency according to IUPAC referencing with CFCl3 set to 0 ppm. 
 
3. Results and discussion 
As a first identification approach, a methanolic sample solution of the powder and herbal 
incenses were analyzed by GC-MS and major peaks were identified by means of computer 
based library search of the SWGDRUG Mass Spectral Library (Version 3.0) (15) and 
Cayman Spectral Library (Version 05202016) (16) installed on the Agilent ChemStation. The 
described HPLC-PDA method was applied as part of laboratories systematic identification 
scheme of powders (ISO/IEC 17025:2005 accredited) using an in-house UV-spectrum 
database. No library hit was found. Also the search on Forendex, provided through the 
Southern Association of Forensic Scientists (17), did not result in the identification of the 
major compound. The analytical information obtained with the routine GC-MS and HPLC-
PDA identification approach and the extended analysis by ESI-LC-MS, ESI-HRMS and 
NMR are summarized below. 
 
3.1 GC-MS 
As shown in Figure 2, a major peak at 26.5 min.was detected in the total ion chromatogram 
of the methanolic sample extracts of the herbal incenses. The retention time and mass 
spectrum was in accordance with the 5F-MDMB-PICA peak in the methanolic solution of the 
brown powder. The mass spectrum of 5F-MDMA-PICA and proposed fragmentation is given 
in Figure 2. 
 
3.3 HPLC-PDA 
As illustrated in Figure 3, the chromatographic profile obtained after injection of the 
methanolic sample solution of the powder and crude methanolic extract of the herbal incenses 
are similar. Besides the major peak at 28.24 min., two minor peaks (at retention time 30.06 
min and 31.16 min, respectively) were detected with the same UV-spectrum as the major 
peak 5F-MDMB-PICA, indicating that two structure analogues are present. The UV-
spectrum of the major peak is shown in Figure 3. 
 
3.4 ESI-LC-MS 
The LC-MS chromatogram indicates that material consists of one major component 
(retention time: 7.55 min) alongside several unidentified minor impurities. The ESI-LC-MS 
spectrum of the major component gives two peaks at 377.2 and 753.5 Da which could be 
assigned as the M+H and 2M+H peaks respectively. These values are consistent with earlier 
published literature on 5F-MDMB-PICA (18). Full LC-MS spectral data are shown in Figure 
4.  
 
3.5 ESI-HRMS and molecular formula analysis. 
 The high resolution spectrum for the sample gives two major peaks at 377.2250 and 753. 
4460 ppm which could be assigned as the M+H and 2M+H ions respectively. Minor ions 
appearing in the spectrum could be attributed to M+Na (399.2083) and M+K ions 
(415.1834). Software analysis of the ion at 377.2250 Da pointed towards a molecular formula 
for the M+H ion C12H30N2O3F. These values are consistent with earlier published literature 
on 5F-MDMB-PICA (18). HRMS: [M+H] C12H30N2O3F Calc: 377.2240 found: 377.2250. 
Full HRMS spectral data are shown in Figure 5 and 6. 
 
 3.6 NMR spectroscopy. 
Figure 7 shows the recordings of the NMR spectra for 1H, 13C and 19F, allowing the full 
assignment of all H, C and F atoms in the structure. Peak assignment can be correlated to the 
structure and atom numbering as shown in Figure 8. : 1H NMR (300 MHz, DMSO-d6) δ = 
8.42 (s, 1H, i), 8.12 (dd, J = 8.0 Hz, J = 1.0 Hz, 1H, n), 7.62 (d, J = 8.7 Hz, f), 7.54 (d, J = 8.0 
Hz, 1H, k), 7.19 (dd, J = 8.0 Hz, J = 1.0 Hz , 1H, l), 7.15 (dd, J = 8.0 Hz, J = 1.0Hz, 1H, m), 
7.53 Hz (s, 1H, c), 4.42 (dt, JHF = 47.4 Hz, J = 6.0 Hz, 2H, t), 4.22 (t, J = 7.2 Hz, 2H, p), 3,67 
(s, 3H, a), 1.90-1.80 (m, 2H, q), 1.77-1.59 (brm, 2H, s), 1.42-1.32 (m, 2H, r), 1.04 (s, 9H, e). 
13C NMR (75.4 MHz, DMSO-d6) δ = 172.0 (b), 164.4 (g), 136.1 (j), 131.7 (i), 126.7 (o), 
122.0 (l), 121.2 (n), 120.7 (m), 110.3 (k), 108.7 (h), 83.6 (d, 1JCF = 162 Hz), 60.0 (c), 51.4 (a), 
45.8 (p), 33.8 (d), 29.4 (d, 2JCF = 18.4 Hz, s) 29.3 (q), 26.8 (e), 22.2 (d, 3JCF = 5.8 Hz, r). 
19F NMR (282 MHz, DMSO-d6) δ = -217.0. 
Apart from the principal compound both the 1H and 13C NMR spectra indicate the presence 
of a minor impurity having an ethyl substituent as indicated by the quartet at 3.05 ppm and 
the triplet at 1.2 ppm in the 1H NMR spectrum and the presence of two peaks at 45 and 8 ppm 
in the 13C NMR spectrum. 
 
The full set of applied analytical methods allowed the identification and structural 
characterization of the major compound in the brown powder as a tert-leucinate synthetic 
cannabinoid: 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate or 5F-
MDMB-PICA (synonyms 5F-MDMB-2201, MDMB-2201). Reported IUPAC names for this 
compound include: methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-
dimethylbutanoate; methyl 2-{[1-   (5-fluoropentyl)-1H-indol-3-yl]formamido}-3,3-
dimethylbutanoate and N-[[1-(5-fluoropentyl)-1H-indol-3-yl]carbonyl]-3-methyl-L-valine, 
methyl ester).  
All packages of “spice-like” herbal incenses were analyzed with GC-MS and HPLC-PDA. 
The presence of this synthetic cannabinoid was confirmed based on retention time and 
similarity index or mass spectrum. 
 
5F-MDMB-PICA is structurally related to the previously identified synthetic cannabinoids 
5F-MDMB-PINACA (synonyms: 5F-ADB, MDMB(N)-2201), differing by the replacement 
of the indazole core with an indole core (19-20). The chemical structure of tert-leucinate 
synthetic cannabinoids are shown in Figure 9 (18).  
A PubMed search demonstrates the lack of information in the NPS field: only a single 
reference whatsoever was found for the substance. Banister et al. (18) studied the 
pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 
5F-ADB, AMB-FUBINICA, MDMB-FUBINICA, MDMB-CHMICA and their analogues. 
In October 2016, the Joint Research Centre, the European Commission’s in house science 
service, reported the analysis of a pink-orange powder received from the Belgian Customs 
laboratory, confirmed to be 5F-MDMB-PICA (21). 
 
4. Conclusions 
The full set of applied analytical methods allowed the identification and structural 
characterization of the synthetic cannabinoid  methyl 2-[[1-(5-fluoropentyl)indole-3-
carbonyl]amino]-3,3-dimethyl-butanoate or 5F-MDMB-PICA in powder and as additive in 
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Figure 2. GC-EI-MS total ion chromatogram (diphenylamine: peak at retention time 12.6 
min) of a herbal incense (upper): mass spectrum of the major compound 5F-MDMB-PICA at 







Figure 3. HPLC-PDA-analysis (diphenylamine: peak at retention time 26.93 min): 
chromatogram recorded at 254 nm of the brown powder (upper) and a herbal incense 
(middle), with UV-spectrum of 5F-MDMB-PICA at retention time 28.24 min (lower).  
 
 
Figure 4. LC-MS chromatogram of 5F-MDMB-PICA. 
 
Figure 5. HRMS spectrum of 5F-MDMB-PICA 
Elemental Composition Report 
 
Single Mass Analysis 
Tolerance = 10.0 PPM   /   DBE: min = -1.5, max = 50.0 
Element prediction: Off  
Number of isotope peaks used for i-FIT = 3 
 
Monoisotopic Mass, Even Electron Ions 
656 formula(e) evaluated with 6 results within limits (up to 50 best isotopic matches for each mass) 
 
Elements Used: C: 0-60    H: 0-100    N: 1-5    O: 1-5    F: 0-6     
 
 
Minimum:                                        -1.5 
Maximum:                    5.0       10.0      50.0 
 
Mass        Calc. Mass      mDa       PPM       DBE       i-FIT       i-FIT (Norm)  Formula 
377.2250    377.2240        1.0       2.7       7.5       377.9      0.0           C21  H30  N2  O3  F  
             377.2229        2.1       5.6       11.5      385.2      7.3           C24  H29  N2  O2  
             377.2252        -0.2      -0.5      3.5       385.8      7.8           C18  H31  N2  O4  F2  
             377.2216        3.4       9.0       4.5       386.1      8.2           C19  H29  N2  O  F4  
             377.2263        -1.3      -3.4      0.5      388.5      10.6          C15  H32  N2  O5  F3  
             377.2227        2.3      6.1      0.5      388.6      10.7         C16  H30  N2  O2  F5 
m/z




16-Nov-2016 brown powderEF_F085016 124 (0.968) Cm (124)















Figure 6. HRMS based Molecular ion analysis 
 
 














Figure 9. Chemical structure of tert-leucinate synthetic cannabinoids 
 
